Healthcare group Shalby Limited reported an 11.7% rise in Q1 FY27 consolidated revenue to ₹3.31 billion, backed by hospital operations and a 51% revenue jump in implant manufacturing. Net profit reached ₹108.45 million. The company appointed Shanay Vikram Shah as Whole-Time Director and fully consolidated its Singapore entity.
AHMEDABAD, India — Multi-specialty hospital chain Shalby Limited announced its financial and operational performance for the first quarter ended June 30, 2026, reporting a 11.7% year-on-year increase in consolidated revenue from operations to ₹3.31 billion (₹3,312.24 million). According to regulatory disclosures submitted to Indian stock exchanges on August 12, 2026, the company recorded a consolidated net profit attributable to equity shareholders of ₹108.45 million for the quarter, compared to ₹89.22 million in the same period of the previous fiscal year. The steady financial trajectory reflects continued patient volumes across its core healthcare facilities alongside steady scaling in its implant manufacturing arm.
Financial Performance and Operational Breakdown
In its regulatory filing following the Board of Directors meeting on August 12, 2026, Shalby Limited detailed the financial performance across its primary business segments. The company's total consolidated income for the quarter reached ₹3.386 billion (₹3,386.38 million), up from ₹3.034 billion (₹3,034.34 million) reported in the quarter ended June 30, 2025.
The primary growth engine remained the Healthcare Services segment, which encompasses hospital operations and diagnostic services. Revenue from Healthcare Services rose to ₹2.888 billion (₹2,888.14 million) in Q1 FY27, compared to ₹2.684 billion (₹2,683.63 million) in Q1 FY26. Segment profit before tax for healthcare operations stood at ₹311.76 million, demonstrating stable operational margins across the network.
Concurrently, Shalby Limited’s Manufacturing & Trading of Implants division recorded revenue of ₹424.10 million during the quarter, reflecting a 51.1% increase compared to ₹280.62 million recorded in the corresponding quarter of the previous year. However, the manufacturing segment reported a segment loss of ₹114.81 million for the quarter, compared to a loss of ₹99.15 million in Q1 FY26, as the company continues to invest in scaling global production and distribution channels.
On a standalone basis, Shalby Limited reported revenue from operations of ₹2.538 billion (₹2,537.91 million) for Q1 FY27, up from ₹2.366 billion (₹2,365.64 million) in Q1 FY26. Standalone net profit for the quarter stood at ₹250.66 million, compared to ₹256.95 million in the prior-year period. Consolidated basic and diluted earnings per share (EPS) rose to ₹0.98 per share from ₹0.71 per share in Q1 FY26.
Leadership Restructuring and Corporate Governance
Alongside the financial release, the Board of Directors approved key executive appointments and corporate governance updates during its meeting on August 12, 2026.
The board approved the appointment of Mr. Shanay Vikram Shah as an Additional Director designated as Whole-Time Director for a five-year term effective August 12, 2026, subject to shareholder approval. Aged 35, Mr. Shanay Shah holds a Bachelor of Science in Accounting and Finance from the University of Warwick, a Master’s degree in International Health Management from Imperial College London, and is a Chartered Financial Analyst (CFA). He has over a decade of experience within the organization, overseeing international operations, finance, and strategic planning.
In addition, the board approved the appointment of PricewaterhouseCoopers Services LLP, Chartered Accountants, as the internal auditors of Shalby Limited for the financial year 2026–27. The company also announced that its 22nd Annual General Meeting (AGM) will take place virtually on Thursday, September 10, 2026, at 4:00 p.m. IST.
Strategic Consolidation of International Operations
Shalby Limited also confirmed the full corporate integration of its overseas business arm. Its wholly-owned subsidiary, Shalby Medtech Limited (formerly Mars Medical Devices Limited), acquired the remaining 0.67% equity stake (10,000 equity shares) in Singapore-based Shalby Global Technologies Pte. Ltd. from promoter shareholders Dr. Vikram Shah and Mr. Shanay Shah for SGD 20,000.
Following this transaction, completed on August 12, 2026, Shalby Global Technologies Pte. Ltd. became a 100% wholly-owned step-down subsidiary of Shalby Limited. The entity, engaged in the wholesale distribution of medical equipment, reported a turnover of SGD 911,671 for the fiscal year 2025–26.
Official Sources Section
According to official filings submitted by Vice President and Company Secretary Tushar Shah to the stock exchanges, all financial evaluations were reviewed by the Audit Committee and subsequently approved by the Board of Directors on August 12, 2026. Statutory Auditors T R Chadha & Co LLP issued an unmodified Limited Review Report on both standalone and consolidated financial statements for the quarter ended June 30, 2026.
Quote Section
According to official statements within the regulatory disclosure:
"The Board of Directors at its meeting held today, August 12, 2026, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The board has also approved strategic management appointments and internal audit mandates to align with the company's long-term growth objectives."
Why It Matters
The Q1 FY27 results signal operational stability in Shalby Limited's core hospital network alongside aggressive scaling in its orthopedic implant business. For retail investors and healthcare market analysts, the 51.1% top-line expansion in implant manufacturing highlights progress in diversification, while full ownership of Singapore-based distribution assets streamlines global supply chains. Patients and consumers benefit from continued institutional investments in multi-specialty clinical governance and facility expansions.
Key Facts at a Glance
Consolidated Revenue: ₹3.31 billion (₹3,312.24 million) in Q1 FY27, up 11.7% YoY.
Consolidated Net Profit: ₹108.45 million attributable to shareholders, up 21.5% YoY.
Implant Division Growth: Implant manufacturing revenue expanded 51.1% YoY to ₹424.10 million.
Leadership Update: Shanay Vikram Shah appointed Whole-Time Director for a 5-year term.
International Corporate Restructuring: Shalby Global Technologies Pte. Ltd. becomes a 100% wholly-owned step-down subsidiary.
FAQ Section
Q1: What were Shalby Limited's main revenue figures for Q1 FY27?
Shalby reported consolidated revenue from operations of ₹3.31 billion (₹3,312.24 million) for the quarter ended June 30, 2026, representing an 11.7% growth compared to ₹2.96 billion in Q1 FY26.
Q2: How did Shalby's healthcare services and implant divisions perform individually?
Healthcare services revenue reached ₹2.888 billion with segment profits of ₹311.76 million. Implant manufacturing revenue increased to ₹424.10 million, though the segment posted a loss of ₹114.81 million due to ongoing scaling expenses.
Q3: Who was appointed to Shalby Limited's Board of Directors?
The board approved the appointment of Mr. Shanay Vikram Shah as Additional Director designated as Whole-Time Director for five years starting August 12, 2026, subject to shareholder approval.
Q4: When is Shalby Limited's Annual General Meeting scheduled?
The company’s 22nd Annual General Meeting (AGM) will take place on Thursday, September 10, 2026, at 4:00 p.m. IST.
Source: Official regulatory disclosures and outcome of board meeting filings submitted to the National Stock Exchange of India Ltd., BSE Limited, and Shalby Limited Investor Relations.
